REGN vs VRT · P/E 14, rev $14.34B vs P/E 80, rev $10.23B
Regeneron Pharmaceuticals Inc (REGN) versus Vertiv Holdings Co (VRT) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Vertiv Holdings Co (VRT) is a electrical equipment & parts company listed on NYSE.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported VRT revenue for 2025-12-31 was $10.23B. Net income was $1.33B. Revenue was up 27.7% from 2024-12-31 to 2025-12-31. VRT currently screens at market cap $121.99B and trailing P/E 79.8.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. VRT currently screens at market cap $121.99B and trailing P/E 79.8.
Not investment advice. Open the REGN and VRT stock pages for the full models.
Not investment advice.